Articles related to Hematology/Oncology

The emergence of novel agents including BTK degraders, next-generation BCL2 inhibitors, and optimized combination approaches is reshaping the CLL treatment landscape, with multiple trials demonstrating high uMRD rates, improved progression-free survival, and manageable toxicity profiles across different patient populations.

Flow cytometric evaluation of MRD in AML demonstrates that blast phenotypes consistently show abnormalities but may evolve during treatment, emphasizing the importance of comprehensive antigen panel analysis for accurate detection.

Digital platforms are enabling oncologists to access global expertise through virtual tumor boards, particularly benefiting practitioners in resource-limited settings who previously lacked access to multidisciplinary consultation.

The phase 3 ALLELE trial demonstrated tabelecleucel’s potential with a 50.7% overall response rate and median duration of response of 23.0 months in EBV+ PTLD patients.

Early cancer detection through AI-analyzed blood tests could lead to personalized mRNA vaccine production in just 48 hours, according to Oracle CEO Larry Ellison.

Fixed-duration venetoclax-based therapy demonstrates sustained efficacy in CLL, with 65.2% of first-line patients remaining treatment-free five years after completion.